Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

KLRS

Kalaris Therapeutics Inc

Apr 28 • 04:00PM ET

5.64

-0.38 -6.40 %

Healthcare • Biotechnology • USA • Micro • NASD

Held by: VTI VXF SURI IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.20	Insider Own	67.26%	Shs Outstand	22.90M	Perf Week	-10.27%
Market Cap	118.13M	Forward P/E	-	EPS next Y	-1.48	Insider Trans	3.51%	Shs Float	7.51M	Perf Month	4.55%
Enterprise Value	1.60M	PEG	-	EPS next Q	-0.52	Inst Own	19.80%	Short Float	11.22%	Perf Quarter	-41.36%
Income	-43.44M	P/S	-	EPS this Y	23.04%	Inst Trans	14.22%	Short Ratio	12.64	Perf Half Y	18.13%
Sales	0.00M	P/B	1.64	EPS next Y	32.37%	ROA	-36.16%	Short Interest	0.84M	Perf YTD	-33.23%
Book/sh	3.44	P/C	1.00	EPS next 5Y	10.99%	ROE	-45.22%	52W High	11.88 -52.57%	Perf Year	-16.02%
Cash/sh	5.63	P/FCF	-	EPS past 3/5Y	61.69% 45.59%	ROIC	-54.33%	52W Low	2.14 163.32%	Perf 3Y	-92.88%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.05% 9.47%	Perf 5Y	-98.94%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	64.30%	Oper. Margin	-	ATR (14)	0.57	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	12.23	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	37.01	Recom	1.33
Dividend Gr. 3/5Y	- -	Current Ratio	12.23	EPS Q/Q	88.00%	SMA20	-8.31%	Beta	0.21	Target Price	19.50
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	-26.78%	Rel Volume	2.30	Prev Close	6.02
Employees	20	LT Debt/Eq	0.01	Earnings	Mar 17 BMO	SMA200	-10.48%	Avg Volume	66.67K	Price	5.64
IPO	Jul 30, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	8.75% -	Trades		Volume	153,194	Change	-6.40%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-16-26	Initiated	Morgan Stanley	Overweight	$14
Dec-23-25	Initiated	Chardan Capital Markets	Buy	$19
Nov-03-25	Initiated	Citizens JMP	Mkt Outperform	$20
Sep-03-25	Initiated	Raymond James	Strong Buy	$23
Jul-23-25	Resumed	Piper Sandler	Neutral	$3
May-07-25	Initiated	Leerink Partners	Outperform	$20
Apr-08-25	Initiated	William Blair	Outperform

Jan-28-26 04:05PM	Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting (GlobeNewswire)
Dec-17-25 05:59PM	Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement (GlobeNewswire) +20.32%
04:01PM	Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naive Neovascular AMD (GlobeNewswire)
Nov-24-25 08:00AM	Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference (Newsfile) -7.99%
Nov-12-25 08:00AM	Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
07:30AM	Loading…
Nov-03-25 07:30AM	Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer (GlobeNewswire)
Oct-30-25 08:00AM	Kalaris to Present at Stifel 2025 Annual Healthcare Conference (GlobeNewswire)
Sep-15-25 03:26PM	UPDATE - Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration (GlobeNewswire)
08:00AM	Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration (GlobeNewswire)
Sep-01-25 12:00PM	Kalaris Therapeutics Inc. (KLRS) Upgraded to Buy: Here's What You Should Know (Zacks)
Aug-13-25 08:00AM	Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) -8.43%
Jun-02-25 08:00AM	Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference (GlobeNewswire)
May-23-25 11:03AM	Kalaris to Participate at Stifel Ophthalmology Forum (GlobeNewswire)
May-14-25 08:00AM	Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire)
Apr-04-25 08:00AM	Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee (GlobeNewswire)
04:21PM	Loading…
Mar-18-25 04:21PM	Kalaris Announces Closing of Merger with AlloVir (GlobeNewswire) +16.92%

Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. It is focusing on developing TH103, a novel anti-VEGF agent targeted at treating neovascular and exudative retinal diseases. The company was founded by Srinivas Akkaraju, Mike Dybbs and Napoleone Ferrara in 2019 and is headquartered in Berkeley Heights, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hagen Brett R	Chief Accounting Officer	Mar 20 '26	Sale	6.72	1,915	12,869	0	Mar 23 04:05 PM
BRETT R R HAGEN	Officer	Mar 20 '26	Proposed Sale	6.72	1,915	12,869		Mar 20 04:07 PM
AKKARAJU SRINIVAS	Director	Dec 18 '25	Buy	10.42	479,847	5,000,006	1,979,847	Feb 17 08:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KLRS

Kalaris Therapeutics Inc

Upgrade your Finviz experience